Exelixis (EXEL) recently announced results from its global phase 3 STELLAR-303 trial, which evaluated zanzalintinib with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback